<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id><journal-id journal-id-type="publisher-id">JCMM</journal-id><journal-title-group><journal-title>Journal of Cellular and Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1582-1838</issn><issn pub-type="epub">1582-4934</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29992789</article-id><article-id pub-id-type="pmc">6111871</article-id><article-id pub-id-type="doi">10.1111/jcmm.13732</article-id><article-id pub-id-type="publisher-id">JCMM13732</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Aldolase A as a prognostic factor and mediator of progression via inducing epithelial&#x02013;mesenchymal transition in gastric cancer</article-title><alt-title alt-title-type="left-running-head">JIANG et al.</alt-title></title-group><contrib-group><contrib id="jcmm13732-cr-0001" contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Zhonghua</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7526-5877</contrib-id><address><email>jiangzhonghua1982@163.com</email></address><xref ref-type="aff" rid="jcmm13732-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcmm13732-cr-0002" contrib-type="author"><name><surname>Wang</surname><given-names>Xiaohong</given-names></name><xref ref-type="aff" rid="jcmm13732-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcmm13732-cr-0003" contrib-type="author"><name><surname>Li</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="jcmm13732-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcmm13732-cr-0004" contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Hongmei</given-names></name><address><email>196206yhm@163.com</email></address><xref ref-type="aff" rid="jcmm13732-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcmm13732-cr-0005" contrib-type="author"><name><surname>Lin</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="jcmm13732-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="jcmm13732-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>The First People's Hospital of Yancheng</institution>
<named-content content-type="city">Yancheng</named-content>
<country country="CN">China</country>
</aff><aff id="jcmm13732-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>The Second Affiliated Hospital of Xuzhou Medical University</institution>
<named-content content-type="city">Xuzhou, Jiangsu</named-content>
<country country="CN">China</country>
</aff><aff id="jcmm13732-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Departments of CyberKnife</named-content>
<named-content content-type="organisation-division">Huashan Hospital</named-content>
<institution>Fudan University</institution>
<named-content content-type="city">Shanghai</named-content>
<country country="CN">China</country>
</aff><aff id="jcmm13732-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Digestive Endoscopy</named-content>
<institution>The First People's Hospital of Wujiang District</institution>
<named-content content-type="city">Suzhou</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Zhonghua Jiang and Hongmei Yang<break/>
Emails: <email>jiangzhonghua1982@163.com</email> (ZJ) and <email>196206yhm@163.com</email> (HY)<break/></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2018</year></pub-date><volume>22</volume><issue>9</issue><issue-id pub-id-type="doi">10.1111/jcmm.2018.22.issue-9</issue-id><fpage>4377</fpage><lpage>4386</lpage><history><date date-type="received"><day>11</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>24</day><month>5</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &#x00026; Sons Ltd and Foundation for Cellular and Molecular Medicine.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JCMM-22-4377.pdf"/><abstract id="jcmm13732-abs-0001"><title>Abstract</title><p>Glycolysis is regarded as the hallmark of cancer development and progression, which involves a multistep enzymatic reaction. This study aimed to explore the clinicopathological significance and potential role of glycolytic enzyme aldolase A (<styled-content style="fixed-case">ALDOA</styled-content>) in the carcinogenesis and progression of gastric cancer (<styled-content style="fixed-case">GC</styled-content>). <styled-content style="fixed-case">ALDOA</styled-content> was screened from three paired liver metastasis tissues and primary <styled-content style="fixed-case">GC</styled-content> tissues and further explored with clinical samples and in vitro studies. The <styled-content style="fixed-case">ALDOA</styled-content> protein level significantly correlated with a larger tumor diameter (<italic>P</italic> = .004), advanced T stage (<italic>P</italic> &#x0003c; .001), N stage (<italic>P</italic> &#x0003c; .001) and lymphovascular invasion (<italic>P</italic> = .001). Moreover, the expression of <styled-content style="fixed-case">ALDOA</styled-content> was an independent prognostic factor for the 5&#x02010;year overall survival and disease&#x02010;free survival of patients with <styled-content style="fixed-case">GC</styled-content> in both univariate and multivariate survival analyses (<italic>P</italic> &#x0003c; .05). Silencing the expression of <styled-content style="fixed-case">ALDOA</styled-content> in <styled-content style="fixed-case">GC</styled-content> cell lines significantly impaired cell growth, proliferation and invasion ability (<italic>P</italic> &#x0003c; .05). Knockdown of the expression of <styled-content style="fixed-case">ALDOA</styled-content> reversed the epithelial&#x02013;mesenchymal transition process. Mechanically, <styled-content style="fixed-case">ALDOA</styled-content> could affect the hypoxia&#x02010;inducible factor (<styled-content style="fixed-case">HIF</styled-content>)&#x02010;1&#x003b1; activity as demonstrated by the <styled-content style="fixed-case">HIF</styled-content>&#x02010;1&#x003b1; response element&#x02013;luciferase activity in <styled-content style="fixed-case">GC</styled-content> cells. Collectively, this study revealed that <styled-content style="fixed-case">ALDOA</styled-content> was a potential biomarker of <styled-content style="fixed-case">GC</styled-content> prognosis and was important in the carcinogenesis and progression of human <styled-content style="fixed-case">GC</styled-content>.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jcmm13732-kwd-0001"><styled-content style="fixed-case">ALDOA</styled-content></kwd><kwd id="jcmm13732-kwd-0002">epithelial&#x02013;mesenchymal transition</kwd><kwd id="jcmm13732-kwd-0003">gastric cancer</kwd><kwd id="jcmm13732-kwd-0004">survival analysis</kwd></kwd-group><counts><fig-count count="6"/><table-count count="3"/><page-count count="10"/><word-count count="5427"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jcmm13732</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.4 mode:remove_FC converted:28.08.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jcmm13732-cit-1001">
<string-name>
<surname>Jiang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>X</given-names>
</string-name>. <article-title>Aldolase A as a prognostic factor and mediator of progression via inducing epithelial&#x02013;mesenchymal transition in gastric cancer</article-title>. <source xml:lang="en">J Cell Mol Med</source>. <year>2018</year>;<volume>22</volume>:<fpage>4377</fpage>&#x02013;<lpage>4386</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13732</pub-id>
</mixed-citation>
</p><fn-group id="jcmm13732-ntgp-0001"><fn fn-type="equal" id="jcmm13732-note-1001"><p>Jiang and Wang equally contributed to this work.</p></fn></fn-group></notes></front><body><sec id="jcmm13732-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Gastric cancer (GC) is one of the most common and deadliest malignancies worldwide, especially in East Asia.<xref rid="jcmm13732-bib-0001" ref-type="ref">1</xref> Despite recent advancements in diagnosis and therapeutic methods, the prognosis of GC is still poor and the 5&#x02010;year survival rate for patients with GC has remained 20%&#x02010;25%<sup>.</sup>
<xref rid="jcmm13732-bib-0002" ref-type="ref">2</xref>, <xref rid="jcmm13732-bib-0003" ref-type="ref">3</xref> The survival of patients largely depends on the disease stage at diagnosis. The tumour&#x02013;node&#x02013;metastasis staging system has been widely used as an effective approach to predict the prognosis of and determine the treatment option for GC. However, the challenges of considerable prognostic heterogeneity within each tumour stage need to be faced, as tumours at the same pathological stage can produce considerably different clinical outcomes,<xref rid="jcmm13732-bib-0004" ref-type="ref">4</xref>, <xref rid="jcmm13732-bib-0005" ref-type="ref">5</xref>, <xref rid="jcmm13732-bib-0006" ref-type="ref">6</xref>, <xref rid="jcmm13732-bib-0007" ref-type="ref">7</xref> highlighting the urgency for identification of other factors, such as the molecular mechanisms that influence metastases and prognosis of GC. Identifying biomarkers for early diagnosis and progression could help explain the biochemical mechanism underlying the processes of metastasis and progression as well as therapeutic sensitivity.</p><p>Tumour cells proliferate at a rapid rate and are always in a hypoxic microenvironment. Cancer cells develop adaptive responses to hypoxia by activating the hypoxia&#x02010;inducible genes to overcome this harsh environment.<xref rid="jcmm13732-bib-0008" ref-type="ref">8</xref>, <xref rid="jcmm13732-bib-0009" ref-type="ref">9</xref>, <xref rid="jcmm13732-bib-0010" ref-type="ref">10</xref> Under this circumstance, hypoxia is a major characteristic of cancer; in hypoxic conditions, cancer cells develop metabolism reprogram from oxidative phosphorylation to glycolysis.<xref rid="jcmm13732-bib-0011" ref-type="ref">11</xref>, <xref rid="jcmm13732-bib-0012" ref-type="ref">12</xref> A feature of this phenomenon is increased lactate production even at normal oxygen concentrations. This phenomenon is named as the Warburg effect or aerobic glycolysis. The Warburg effect was considered to be at the root of carcinogenesis and progression.<xref rid="jcmm13732-bib-0003" ref-type="ref">3</xref>, <xref rid="jcmm13732-bib-0013" ref-type="ref">13</xref>, <xref rid="jcmm13732-bib-0014" ref-type="ref">14</xref> It not only provides cancer cells with adenosine triphosphate (ATP) and nutrients but also leads to an acidic environment that facilitates metastasis.<xref rid="jcmm13732-bib-0003" ref-type="ref">3</xref> Glycolysis represents a 10&#x02010;step metabolic process that involves multiple enzymes.<xref rid="jcmm13732-bib-0015" ref-type="ref">15</xref> Studies have shown that some glycolytic enzymes are more complicated and multifaceted proteins than simple components of the glycolytic enzymes.<xref rid="jcmm13732-bib-0016" ref-type="ref">16</xref> These glycolytic enzymes have acquired additional non&#x02010;glycolytic functions in many aspects.<xref rid="jcmm13732-bib-0017" ref-type="ref">17</xref>
</p><p>In this study, quantitative reverse transcriptase&#x02013;polymerase chain reaction (qRT&#x02010;PCR) arrays of glycolysis&#x02010;related enzymes were performed in three paired liver metastasis tissues and primary GC tissues. Aldolase A (ALDOA) was chosen for further study. This study mainly investigated the expression of ALDOA in GC tissues and its clinical significance and biological function in GC cells and also elucidated the mechanisms underlying the regulatory role of ALDOA in GC cells.</p></sec><sec id="jcmm13732-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="jcmm13732-sec-0003"><label>2.1</label><title>Patients and samples</title><p>A series of 252 patients with pathologically confirmed GC was used for the immunohistochemical (IHC) study to explore the clinical significance of the expression of ALDOA in GC. All patients who had no neoadjuvant chemotherapy and received radical gastrectomy were randomly selected from samples collected between 2008 and 2012. The median follow&#x02010;up time was 46 months. The characteristics of the samples are shown in Table <xref rid="jcmm13732-tbl-0001" ref-type="table">1</xref>.</p><table-wrap id="jcmm13732-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Association between the expression of ALDOA and clinicopathological factors in gastric cancers</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1">Characteristics</th><th align="left" rowspan="3" valign="top" colspan="1">Total</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">ALDOA expression</th><th align="left" rowspan="3" valign="top" colspan="1">
<italic>P</italic> value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Low expression</th><th align="left" valign="top" rowspan="1" colspan="1">High expression</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Gender</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">134</td><td align="left" rowspan="1" colspan="1">44 (32.8)</td><td align="left" rowspan="1" colspan="1">90 (67.2)</td><td align="left" rowspan="2" colspan="1">.197</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1">30 (25.4)</td><td align="left" rowspan="1" colspan="1">88 (74.6)</td></tr><tr><td align="left" colspan="5" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;60</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">34 (30.5)</td><td align="left" rowspan="1" colspan="1">87 (69.5)</td><td align="left" rowspan="2" colspan="1">.672</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;60</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">40 (28.1)</td><td align="left" rowspan="1" colspan="1">91 (71.9)</td></tr><tr><td align="left" colspan="5" rowspan="1">Primary site</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antrum/distal</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">26 (27.4)</td><td align="left" rowspan="1" colspan="1">69 (72.6)</td><td align="left" rowspan="4" colspan="1">.076</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cardia/proximal</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">28 (32.6)</td><td align="left" rowspan="1" colspan="1">58 (67.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fundus/body</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">18 (37.5)</td><td align="left" rowspan="1" colspan="1">30 (62.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gastroesophageal junction</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">2 (8.7)</td><td align="left" rowspan="1" colspan="1">21 (91.3)</td></tr><tr><td align="left" colspan="5" rowspan="1">Diameter (cm)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;4</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">37 (40.2)</td><td align="left" rowspan="1" colspan="1">55 (59.8)</td><td align="left" rowspan="2" colspan="1">
<bold>.004</bold>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;4</td><td align="left" rowspan="1" colspan="1">160</td><td align="left" rowspan="1" colspan="1">37 (23.1)</td><td align="left" rowspan="1" colspan="1">123 (76.9)</td></tr><tr><td align="left" colspan="5" rowspan="1">Histologic grade</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">G1/G2</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">38 (35.2)</td><td align="left" rowspan="1" colspan="1">70 (64.8)</td><td align="left" rowspan="2" colspan="1">.079</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">G3</td><td align="left" rowspan="1" colspan="1">144</td><td align="left" rowspan="1" colspan="1">36 (25.0)</td><td align="left" rowspan="1" colspan="1">108 (75.0)</td></tr><tr><td align="left" colspan="5" rowspan="1">T stage</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">T1/2</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">27 (61.4)</td><td align="left" rowspan="1" colspan="1">17 (38.6)</td><td align="left" rowspan="3" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">T3</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">24 (21.8)</td><td align="left" rowspan="1" colspan="1">86 (78.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">T4</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">23 (23.5)</td><td align="left" rowspan="1" colspan="1">75 (76.5)</td></tr><tr><td align="left" colspan="5" rowspan="1">N stage</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">N0</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">36 (52.1)</td><td align="left" rowspan="1" colspan="1">33 (47.8)</td><td align="left" rowspan="4" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">N1</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">10 (19.2)</td><td align="left" rowspan="1" colspan="1">42 (80.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">N2</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">9 (15.5)</td><td align="left" rowspan="1" colspan="1">49 (84.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">N3</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">19 (26.0)</td><td align="left" rowspan="1" colspan="1">54 (74.0)</td></tr><tr><td align="left" colspan="5" rowspan="1">Lymphovascular invasion</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">196</td><td align="left" rowspan="1" colspan="1">68 (34.7)</td><td align="left" rowspan="1" colspan="1">128 (65.3)</td><td align="left" rowspan="2" colspan="1">
<bold>.001</bold>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">6 (10.7)</td><td align="left" rowspan="1" colspan="1">50 (89.3)</td></tr><tr><td align="left" colspan="5" rowspan="1">Perineural invasion</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">185</td><td align="left" rowspan="1" colspan="1">58 (31.4)</td><td align="left" rowspan="1" colspan="1">127 (68.6)</td><td align="left" rowspan="2" colspan="1">.250</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">16 (23.9)</td><td align="left" rowspan="1" colspan="1">51 (76.1)</td></tr></tbody></table><table-wrap-foot><fn id="jcmm13732-note-0002"><p>Bold type indicates statistical significance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>This study was performed in compliance with the Helsinki Declaration. The use of clinical samples was approved by the Human Ethics Review Committee of the First People's Hospital of Yancheng, Yancheng, China. Written informed consent was obtained from all patients included in the study.</p></sec><sec id="jcmm13732-sec-0004"><label>2.2</label><title>Cell lines</title><p>Human gastric adenocarcinoma cell lines, AGS and MGC&#x02010;803, were originally obtained from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in the Dulbecco's modified Eagle's medium containing 10% foetal bovine serum, 100 U/mL penicillin and 100 &#x003bc;g/mL streptomycin in a 37&#x000b0;C incubator supplied with 5% CO<sub>2</sub>.</p></sec><sec id="jcmm13732-sec-0005"><label>2.3</label><title>Western blot analysis</title><p>Protein extracts (50 mg) were resolved on 10% sodium dodecyl sulphate&#x02013;polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membranes (0.45 mm), and immunoblotted with rabbit anti&#x02010;human ALDOA antibody (11217&#x02010;1&#x02010;AP; 1:1000; Proteintech), anti&#x02010;E&#x02010;cadherin antibody (ab40772; 1:1000; Abcam), anti&#x02010;N&#x02010;cadherin antibody (ab18203; 1:1000; Abcam), anti&#x02010;Vimentin (ab92547; 1:1000; Abcam) or mouse anti&#x02010;human &#x003b2;&#x02010;actin monoclonal antibody (ab133626; 1:1000; Abcam). Images were developed using ECL (Pierce, Thermo Scientific, USA).</p></sec><sec id="jcmm13732-sec-0006"><label>2.4</label><title>qPCR</title><p>The total RNA was extracted from cell lines using the TRIzol reagent (Invitrogen, CA, USA). qRT&#x02010;PCR was performed using the RNA PCR kit (TaKaRa, Dalian, China) and Fast SYBR Green qPCR Master Mix on Mx3000P (Stratagene, CA, USA) according to the manufacturer's protocol. The expression of &#x003b2;&#x02010;actin was used as an internal control. The primer sequence used was ALDOA&#x02010;F: ATGCCCTACCAATATCCAGCA and ALDOA&#x02010;R: GCTCCCAGTGGACTCATCTG.</p></sec><sec id="jcmm13732-sec-0007"><label>2.5</label><title>IHC staining</title><p>Immunohistochemical staining was performed for ALDOA. Briefly, paraffin sections were baked for 60 minutes at 70&#x000b0;C, deparaffinized in xylene and rehydrated in gradually varied alcohol. Then, the sections were managed with 3% H<sub>2</sub>O<sub>2</sub> to neutralize endogenous peroxidase for 30 minutes. The antigen retrieval was processed with citrate buffer (pH = 6.0) in a pressure cooker. After antigen retrieval, the sections were incubated with ALDOA primary antibody (11217&#x02010;1&#x02010;AP; 1:100; Proteintech) and secondary antibody. The sections were then stained with 3,3&#x02010;diaminobenzidine, terminated in phosphate&#x02010;buffered saline (PBS), and counterstained with haematoxylin. Based on the staining intensity of ALDOA in each case, the grading was as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. The scores 0 and 1 were regarded as low expression and 2 and 3 as high expression. Two observers graded the score of staining intensity independently.</p></sec><sec id="jcmm13732-sec-0008"><label>2.6</label><title>Stable transfection of GC cells</title><p>Biologically active short hairpin RNAs (shRNA) were generated using the lentiviral expression vector pLKO.1&#x02010;puro. The shRNA target sequence for human ALDOA was 5&#x02032;&#x02010;CCATGCTTGCACTCAGAAGTT&#x02010;3&#x02032;. PLKO.1&#x02010;scramble shRNA with limited homology having any known sequences in the human, mouse and rat genomes was used as a negative control. AGS and MGC803 cells were transfected with the pLKO.1&#x02010;shALDOA expression vector or pLKO.1&#x02010;scramble. The cells stably transfected were isolated using puromycin selection to obtain stable ALDOA knockdown cells.</p></sec><sec id="jcmm13732-sec-0009"><label>2.7</label><title>Cell Counting Kit&#x02010;8 assays</title><p>The cells were seeded at a density of 2000 cells/well in 96&#x02010;well plates and incubated. An aliquot of 10 &#x003bc;L of Cell Counting Kit&#x02010;8 solution (CCK&#x02010;8; Dojindo, Kumamoto, Japan) was added to the wells and incubated for 2 hours. The absorbance was measured at 450 nm to calculate the numbers of viable cells in each well. Each measurement was performed in triplicate, and the experiments were repeated twice.</p></sec><sec id="jcmm13732-sec-0010"><label>2.8</label><title>Colony formation assays</title><p>The cells were trypsinized and plated on six&#x02010;well plates (200 cells/well) and cultured for 2 weeks. The colonies were stained with 1% crystal violet for 30 seconds after fixation with 4% paraformaldehyde for 5 minutes. The colonies were counted and defined as &#x0003e;50 cells/colony. Three independent experiments were performed. The data were calculated using paired <italic>t</italic> test.</p></sec><sec id="jcmm13732-sec-0011"><label>2.9</label><title>Transwell migration</title><p>Cell invasion assays were performed using 6.5&#x02010;mm Transwell chambers (8&#x02010;&#x003bc;m pore size, BD). The cells were seeded at a density of 50 000 cells/well into Transwell chambers coated with Matrigel for assays. The wells were washed with PBS after 36 hours of seeding. The cells that had migrated to the basal side of the membrane were fixed and stained with crystal violet, visualized and photographed using a CKX41 microscope (Olympus, Japan) at 200&#x000d7; magnification. Images of three random fields from three replicate wells were obtained, and the cells that had migrated were counted.</p></sec><sec id="jcmm13732-sec-0012"><label>2.10</label><title>Statistical analysis</title><p>Comparisons between groups for statistical significance were performed with a two&#x02010;tailed paired Student's <italic>t</italic> test. The relationship between the expression of ALDOA and clinicopathological characteristics was tested using the chi&#x02010;square test. Survival curves were plotted by the Kaplan&#x02013;Meier method and compared using the log&#x02010;rank test. The significance of various survival&#x02010;related variables was assessed using the Cox regression model in multivariate analysis. All statistical analyses were performed using the SPSS 17.0 statistical software package. A <italic>P</italic> value &#x0003c;.05 was considered statistically significant.</p></sec></sec><sec id="jcmm13732-sec-0013"><label>3</label><title>RESULTS</title><sec id="jcmm13732-sec-0014"><label>3.1</label><title>Glycolytic enzyme ALDOA might promote tumor metastasis in GC</title><p>Glycolysis is a process involving a series of glycolytic enzymes. The qRT&#x02010;PCR assay was performed and the transcriptional expression levels of glycolytic enzymes in three paired GC tissues, and their paired synchronous liver metastasis tissues were measured to identify the glycolytic enzymes involved in gastric cancer metastasis. All patients underwent synchronous primary tumour and liver metastases resection. The results indicated that the up&#x02010;regulated expression of ALDOA and down&#x02010;regulated FBP1 were most significant in liver metastases compared with its primary tumour (Figure <xref rid="jcmm13732-fig-0001" ref-type="fig">1</xref>). As FBP1 has been studied previously,<xref rid="jcmm13732-bib-0018" ref-type="ref">18</xref> ALDOA was chosen for further study.</p><fig fig-type="Figure" xml:lang="en" id="jcmm13732-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Heatmap of differentially expressed genes in three paired primary gastric cancer tissues and liver metastasis using <styled-content style="fixed-case">qRT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content>. The results were normalized by <italic>Z</italic>&#x02010;score. Each column represented a specimen (denoted at the top), and each row represented a gene (denoted to the right). Red colour indicates genes that were up&#x02010;regulated, and green colour indicates genes that were down&#x02010;regulated. P represents primary gastric cancer tissue, and M represents corresponding liver metastasis</p></caption><graphic id="nlm-graphic-1" xlink:href="JCMM-22-4377-g001"/></fig></sec><sec id="jcmm13732-sec-0015"><label>3.2</label><title>ALDOA was overexpressed in GC tissues</title><p>Quantitative reverse transcriptase&#x02013;polymerase chain reaction and IHC staining were performed on 30 pairs of GCs (T) and matched adjacent gastric tissues (N) to explore whether ALDOA was dysregulated in human GC. As shown in Figure <xref rid="jcmm13732-fig-0002" ref-type="fig">2</xref>A, the mRNA expression of ALDOA increased 4.42&#x02010; to 6.94&#x02010;fold in the GC tissues compared with their matched adjacent cervical tissues. As expected, the protein expression of ALDOA was also markedly up&#x02010;regulated in the GC tissues as judged by IHC (Figure <xref rid="jcmm13732-fig-0002" ref-type="fig">2</xref>B,C).</p><fig fig-type="Figure" xml:lang="en" id="jcmm13732-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Aldolase A (<styled-content style="fixed-case">ALDOA</styled-content>) was up&#x02010;regulated in gastric cancer (<styled-content style="fixed-case">GC</styled-content>). A, The <styled-content style="fixed-case">mRNA</styled-content> expression of <styled-content style="fixed-case">ALDOA</styled-content> was found to be significantly up&#x02010;regulated in <styled-content style="fixed-case">GC</styled-content> tissues than in adjacent normal controls in 30 patients with <styled-content style="fixed-case">GC</styled-content> (<italic>P</italic> &#x0003c; .001). B, Examples of immunohistochemical (<styled-content style="fixed-case">IHC</styled-content>) staining of the expression of <styled-content style="fixed-case">ALDOA</styled-content> in <styled-content style="fixed-case">GC</styled-content> (I and <styled-content style="fixed-case">III</styled-content>) and normal gastric tissues (<styled-content style="fixed-case">II</styled-content> and <styled-content style="fixed-case">IV</styled-content>). C, The expression of <styled-content style="fixed-case">ALDOA</styled-content> was significantly higher in <styled-content style="fixed-case">GC</styled-content> tissues than in their adjacent normal control as determined by <styled-content style="fixed-case">IHC</styled-content> staining (&#x003c7;<sup>2</sup> = 8.076, <italic>P</italic> = .004)</p></caption><graphic id="nlm-graphic-3" xlink:href="JCMM-22-4377-g002"/></fig></sec><sec id="jcmm13732-sec-0016"><label>3.3</label><title>Expression of ALDOA correlated with inferior clinicopathological parameters</title><p>Immunohistochemistry of a series of 252 patients with primary GC was performed, including 134 males and 118 females with a mean age of 59 years (range, 21&#x02010;85 years), to investigate the clinicopathological significance of the expression of ALDOA. Of the 252 specimens, the expression of ALDOA was mainly observed in the cytoplasm in the majority of gastric cancerous specimens, with strong expression in 178 (70.6%) patients and weak or negative expression in 74 (29.4%) patients. Associations between the clinicopathological factors and the expression of ALDOA are summarized in Table <xref rid="jcmm13732-tbl-0001" ref-type="table">1</xref>. The increased expression of ALDOA significantly correlated with the depth of tumour invasion (T stage, <italic>P</italic> &#x0003c; .001), lymph node metastasis (N stage, <italic>P</italic> &#x0003c; .001), lymphovascular invasion (<italic>P</italic> = .001) and tumour diameter (<italic>P</italic> = .004) (Table <xref rid="jcmm13732-tbl-0001" ref-type="table">1</xref>). The factors not significantly associated with the staining included age (<italic>P</italic> = .672), sex (<italic>P</italic> = .197), primary tumour site (<italic>P</italic> = .076) and perineural invasion (<italic>P</italic> = .250).</p></sec><sec id="jcmm13732-sec-0017"><label>3.4</label><title>Expression of ALDOA significantly correlated with survival outcomes in GC</title><p>This study further evaluated the relationship between the expression of ALDOA protein and the 5&#x02010;year overall survival (OS) or disease&#x02010;free survival (DFS) of patients. The results revealed a worse OS in patients with higher expression of ALDOA (high vs low expression: 39.2% vs 76.9%, &#x003c7;<sup>2</sup> = 19.635, <italic>P</italic> &#x0003c; .001) (Figure <xref rid="jcmm13732-fig-0003" ref-type="fig">3</xref>A). Similarly, a shorter DFS was also found in patients with a higher expression of ALDOA (high vs low expression: 33.0% vs 70.9%, &#x003c7;<sup>2</sup> = 28.857, <italic>P</italic> &#x0003c; .001) (Figure <xref rid="jcmm13732-fig-0003" ref-type="fig">3</xref>B). Moreover, multivariate survival analysis demonstrated that the expression of ALDOA was an independent prognostic factor for both OS (hazard ratio [HR], 2.596; 95% confidence interval [CI], 1.440&#x02010;4.680, <italic>P</italic> = .002) and DFS (HR, 2.824; 95% CI, 1.667&#x02010;4.783; <italic>P</italic> &#x0003c; .001) (Tables <xref rid="jcmm13732-tbl-0002" ref-type="table">2</xref> and <xref rid="jcmm13732-tbl-0003" ref-type="table">3</xref>). The results of this study implicated that ALDOA might serve as a potential biomarker for survival in clinical practice.</p><fig fig-type="Figure" xml:lang="en" id="jcmm13732-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Strong expression of aldolase A (<styled-content style="fixed-case">ALDOA</styled-content>) correlated with worse survival in patients with gastric cancer (<styled-content style="fixed-case">GC</styled-content>). A, The 5&#x02010;y overall survival (<styled-content style="fixed-case">OS</styled-content>) in the high&#x02010; and low&#x02010;expression <styled-content style="fixed-case">ALDOA</styled-content> groups was 39.2% and 76.9%, respectively (&#x003c7;<sup>2</sup> = 19.635, <italic>P</italic> &#x0003c; .001). B, The 5&#x02010;y disease&#x02010;free survival (<styled-content style="fixed-case">DFS</styled-content>) in the high&#x02010; and low&#x02010;expression <styled-content style="fixed-case">ALDOA</styled-content> groups was 33.0% and 70.9%, respectively (&#x003c7;<sup>2</sup> = 28.857, <italic>P</italic> &#x0003c; .001)</p></caption><graphic id="nlm-graphic-5" xlink:href="JCMM-22-4377-g003"/></fig><table-wrap id="jcmm13732-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Univariate and multivariate Cox proportional hazards analyses of the expression of ALDOA gene and overall survival for patients with gastric cancer</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Factor</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Univariate analysis</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">0.780 (0.514&#x02010;1.183)</td><td align="left" rowspan="1" colspan="1">.242</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.262 (0.832&#x02010;1.915)</td><td align="left" rowspan="1" colspan="1">.273</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diameter</td><td align="left" rowspan="1" colspan="1">1.254 (0.810&#x02010;1.941)</td><td align="left" rowspan="1" colspan="1">.309</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T stage</td><td align="left" rowspan="1" colspan="1">2.029 (1.479&#x02010;2.782)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.267 (0.824&#x02010;1.949)</td><td align="left" rowspan="1" colspan="1">.281</td></tr><tr><td align="left" rowspan="1" colspan="1">N stage</td><td align="left" rowspan="1" colspan="1">1.652 (1.365&#x02010;2.000)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.000</bold>
</td><td align="left" rowspan="1" colspan="1">1.442 (1.124&#x02010;1.850)</td><td align="left" rowspan="1" colspan="1">
<bold>.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade</td><td align="left" rowspan="1" colspan="1">1.694 (1.094&#x02010;2.625)</td><td align="left" rowspan="1" colspan="1">
<bold>.018</bold>
</td><td align="left" rowspan="1" colspan="1">1.179 (0.752&#x02010;1.848)</td><td align="left" rowspan="1" colspan="1">.474</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphovascular invasion</td><td align="left" rowspan="1" colspan="1">2.193 (1.404&#x02010;3.426)</td><td align="left" rowspan="1" colspan="1">
<bold>.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.469 (0.923&#x02010; 2.336)</td><td align="left" rowspan="1" colspan="1">.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion</td><td align="left" rowspan="1" colspan="1">1.835 (1.193&#x02010;2.822)</td><td align="left" rowspan="1" colspan="1">
<bold>.006</bold>
</td><td align="left" rowspan="1" colspan="1">1.813 (1.163&#x02010;2.825)</td><td align="left" rowspan="1" colspan="1">
<bold>.009</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor location</td><td align="left" rowspan="1" colspan="1">1.149 (0.957&#x02010;1.379)</td><td align="left" rowspan="1" colspan="1">.137</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ALDOA</td><td align="left" rowspan="1" colspan="1">3386 (1.909&#x02010;6.008)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td><td align="left" rowspan="1" colspan="1">2.596 (1.440&#x02010;4.680)</td><td align="left" rowspan="1" colspan="1">
<bold>.002</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="jcmm13732-note-0003"><p>CI, confidence interval; HR, hazard ratio.</p></fn><fn id="jcmm13732-note-0004"><p>Bold type indicates statistical significance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="jcmm13732-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Univariate and multivariate Cox proportional hazards analyses of the gene expression of ALDOA and disease&#x02010;free survival for patients with gastric cancer</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Factor</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Univariate analysis</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">0.949 (0.662&#x02010;1.361)</td><td align="left" rowspan="1" colspan="1">.775</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.132 (0.789&#x02010;1.624)</td><td align="left" rowspan="1" colspan="1">.500</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diameter</td><td align="left" rowspan="1" colspan="1">1.187 (0.814&#x02010;1.729)</td><td align="left" rowspan="1" colspan="1">.373</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T category</td><td align="left" rowspan="1" colspan="1">2.068 (1.568&#x02010;2.728)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.504 (1.056&#x02010;2.141)</td><td align="left" rowspan="1" colspan="1">
<bold>.024</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">N stage</td><td align="left" rowspan="1" colspan="1">1.477 (1.260&#x02010;1.732)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.218 (1.001&#x02010;1.483)</td><td align="left" rowspan="1" colspan="1">
<bold>.049</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade</td><td align="left" rowspan="1" colspan="1">1.917 (1.302&#x02010;2.822)</td><td align="left" rowspan="1" colspan="1">
<bold>.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.447 (0.975&#x02010;2.149)</td><td align="left" rowspan="1" colspan="1">.067</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphovascular invasion</td><td align="left" rowspan="1" colspan="1">2.205 (1.497&#x02010;3.248)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.489 (0.992&#x02010;2.235)</td><td align="left" rowspan="1" colspan="1">.055</td></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion</td><td align="left" rowspan="1" colspan="1">1.503 (1.022&#x02010;2.211)</td><td align="left" rowspan="1" colspan="1">
<bold>.038</bold>
</td><td align="left" rowspan="1" colspan="1">1.388 (0.935&#x02010;2.061)</td><td align="left" rowspan="1" colspan="1">.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor location</td><td align="left" rowspan="1" colspan="1">1.069 (0.910&#x02010;1.257)</td><td align="left" rowspan="1" colspan="1">.416</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ALDOA</td><td align="left" rowspan="1" colspan="1">3.722 (2.221&#x02010;6.236)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td><td align="left" rowspan="1" colspan="1">2.824 (1.667&#x02010;4.783)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="jcmm13732-note-0005"><p>CI, confidence interval; HR, hazard ratio.</p></fn><fn id="jcmm13732-note-0006"><p>Bold type indicates statistical significance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jcmm13732-sec-0018"><label>3.5</label><title>ALDOA knockdown inhibited proliferation and invasion of GC cells</title><p>Previous results indicated that ectopic ALDOA portended inferior clinical characteristics and shorter survival time of GC. Thus, it was hypothesized in this study that silencing the expression of ALDOA could inhibit growth and invasion of GC cells. The stable transfection models of the expression of ALDOA silencing in AGS and MGC803 cells were established. RT&#x02010;PCR and Western blot analysis were performed to verify that ALDOA transcriptional and protein levels decreased in both AGS and MGC803 cells after transfection with ALDOA&#x02013;shRNA (Figure <xref rid="jcmm13732-fig-0004" ref-type="fig">4</xref>A,B). CCK&#x02010;8 and colony formation assays demonstrated that the proliferation of both AGS and MGC803 cells transfected with ALDOA&#x02013;shRNA was significantly inactivated compared with that of those transfected with control shRNA (Figure <xref rid="jcmm13732-fig-0004" ref-type="fig">4</xref>C,D). Transwell assay showed that silencing the expression of ALDOA significantly inhibited the invasion of AGS and MGC803 cells <bold>(</bold>Figure <xref rid="jcmm13732-fig-0004" ref-type="fig">4</xref>E) (<italic>P</italic> &#x0003c; .05). These findings suggested that the knockdown of ALDOA repressed proliferation and invasion ability of GC cells.</p><fig fig-type="Figure" xml:lang="en" id="jcmm13732-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Knockdown of the expression of aldolase A (<styled-content style="fixed-case">ALDOA</styled-content>) suppressed the proliferation and invasion abilities of gastric cancer cells. A, Western blot and (B) <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> analysis were performed to determine the knockdown effect of <styled-content style="fixed-case">ALDOA</styled-content> in <styled-content style="fixed-case">AGS</styled-content> and <styled-content style="fixed-case">MGC</styled-content>803 cells. &#x003b2;&#x02010;Actin was used as the loading control. C, The growth curves of <styled-content style="fixed-case">AGS</styled-content> and <styled-content style="fixed-case">MGC</styled-content>803 cells with transfected sh<styled-content style="fixed-case">RNA</styled-content>&#x02013;<styled-content style="fixed-case">ALDOA</styled-content> or scramble sequence. Cell growth was determined using <styled-content style="fixed-case">CCK</styled-content>&#x02010;8. D, A colony formation assay was performed to determine the oncogenic growth of <styled-content style="fixed-case">AGS</styled-content> and <styled-content style="fixed-case">MGC</styled-content>803 cells transfected with sh<styled-content style="fixed-case">RNA</styled-content> or scramble sequence. E, Transwell assays were performed to determine the invasion abilities of sh<styled-content style="fixed-case">RNA</styled-content>&#x02010;<styled-content style="fixed-case">ALDOA</styled-content>&#x02010;transfected <styled-content style="fixed-case">AGS</styled-content> and <styled-content style="fixed-case">MGC</styled-content>803 cells. Values are presented as mean &#x000b1; standard deviation of three independent experiments. *<italic>P</italic> &#x0003c; .05</p></caption><graphic id="nlm-graphic-7" xlink:href="JCMM-22-4377-g004"/></fig></sec><sec id="jcmm13732-sec-0019"><label>3.6</label><title>Expression of altered ALDOA affects epithelial&#x02013;mesenchymal transition induction in human GC cells</title><p>Thus, the expression of ALDOA was associated with GC metastasis and invasion ability. The capability of ALDOA to induce epithelial&#x02013;mesenchymal transition (EMT) in human GC cells was subsequently investigated. The down&#x02010;regulated expression of ALDOA in AGS and MGC803 cells significantly decreased the levels of vimentin, N&#x02010;cadherin, Snail and ZEB1, but increased the expression of E&#x02010;cadherin at both protein and transcriptional levels (Figure <xref rid="jcmm13732-fig-0005" ref-type="fig">5</xref>A,B). Immunofluorescence staining further revealed that E&#x02010;cadherin was strongly induced while N&#x02010;cadherin decreased in ALDOA&#x02013;shRNA&#x02010;transfected cells (Figure <xref rid="jcmm13732-fig-0005" ref-type="fig">5</xref>C). These results indicated that the altered expression of ALDOA affected EMT induction in GC cells.</p><fig fig-type="Figure" xml:lang="en" id="jcmm13732-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Silencing the expression of aldolase A (<styled-content style="fixed-case">ALDOA</styled-content>) suppressed the epithelial&#x02013;mesenchymal transition in gastric cancer. Silencing the expression of <styled-content style="fixed-case">ALDOA</styled-content> resulted in the increased expression of E&#x02010;cadherin and decreased expression of vimentin, N&#x02010;cadherin, Snail and <styled-content style="fixed-case">ZEB</styled-content>1, at both the protein (A) and transcriptional levels (B). C, Confocal microscopic analysis of phenotypic markers, including E&#x02010;cadherin, crystal violet and vimentin. The red signal represents the staining of corresponding protein and the blue signal represents the nuclear <styled-content style="fixed-case">DNA</styled-content> staining using 4&#x02032;,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole</p></caption><graphic id="nlm-graphic-9" xlink:href="JCMM-22-4377-g005"/></fig></sec><sec id="jcmm13732-sec-0020"><label>3.7</label><title>ALDOA affected hypoxia&#x02010;inducible factor&#x02010;1&#x003b1; activity in GC</title><p>Hypoxia&#x02010;inducible factor (HIF)&#x02010;1&#x003b1; is critical for tumour growth and metastases, in part by inducing glycolytic enzymes and EMT process. Glycolysis is also necessary for maintaining HIF&#x02010;1&#x003b1; activity. Therefore, it is possible that ALDOA can affect the HIF&#x02010;1&#x003b1; activity in GC. HIF&#x02010;1&#x003b1; acts by binding to the HIF&#x02010;1&#x003b1; response element (HRE) upon hypoxia. Therefore, this study used HRE&#x02010;luciferase reporter to examine whether ALDOA affected HRE&#x02010;luciferase activities. As expected, ALDOA could increase HRE&#x02010;luciferase activity in a dose&#x02010;dependent manner (Figure <xref rid="jcmm13732-fig-0006" ref-type="fig">6</xref>A). Moreover, HRE activity could be inhibited by reducing the expression of ALDOA using its specific shRNA (Figure <xref rid="jcmm13732-fig-0006" ref-type="fig">6</xref>B), implying that ALDOA indeed affected the HIF&#x02010;1&#x003b1; activity.</p><fig fig-type="Figure" xml:lang="en" id="jcmm13732-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Aldolase A (<styled-content style="fixed-case">ALDOA</styled-content>) affected the <styled-content style="fixed-case">HIF</styled-content>&#x02010;1&#x003b1; activity in gastric cancer. A, It could increase the <styled-content style="fixed-case">HRE</styled-content>&#x02010;luciferase activity in a dose&#x02010;dependent manner (<italic>P</italic> &#x0003c; .05). B, Silencing the expression of <styled-content style="fixed-case">ALDOA</styled-content> decreased the <styled-content style="fixed-case">HRE</styled-content> activity (<italic>P</italic> &#x0003c; .05)</p></caption><graphic id="nlm-graphic-11" xlink:href="JCMM-22-4377-g006"/></fig></sec></sec><sec id="jcmm13732-sec-0021"><label>4</label><title>DISCUSSION</title><p>Great attention has been paid to glycolytic enzymes as potential therapeutic targets because the cancer&#x02010;specific metabolism depends more on the glycolytic pathway than on aerobic respiration, a phenomenon called the Warburg effect.<xref rid="jcmm13732-bib-0008" ref-type="ref">8</xref> This is a novel study that characterized the importance of ALDOA in GC. First, ALDOA was screened out by performing qRT&#x02010;PCR arrays of a panel of glycolysis&#x02010;related genes in three paired liver metastasis tissues and primary GC tissues. Then, the clinical significance and potential mechanisms by which ALDOA mediated GC metastases and progression were explored in detail. In fact, ALDOA has been validated as an oncogene in some solid tumours. In the pancreas, it promotes tumorigenesis and progression into a highly metastatic pancreatic cancer by regulating the expression of E&#x02010;cadherin.<xref rid="jcmm13732-bib-0019" ref-type="ref">19</xref> It regulates the cell cycle in non&#x02010;small cell lung cancer and several solid tumours.<xref rid="jcmm13732-bib-0020" ref-type="ref">20</xref>
</p><p>One of the most important findings in the present study was a direct relationship between the expression of ALDOA and the inferior clinicopathological features, and the high expression of ALDOA was an independent prognostic factor for both OS and DFS. The functional study indicated that silencing the expression of ALDOA impaired the proliferation and invasion abilities of GC cells. As EMT is the initial step of cancer metastases, the relationship between the expression of ALDOA and EMT&#x02010;related marker was further validated, which suggested that ALDOA might promote tumour metastases by inducing the EMT process.</p><p>HIF&#x02010;1&#x003b1; is critical for cancer cell survival and metastases in the solid tumour under stressed hypoxic tumour environment, in part by inducing glycolytic enzymes and EMT process.<xref rid="jcmm13732-bib-0021" ref-type="ref">21</xref>, <xref rid="jcmm13732-bib-0022" ref-type="ref">22</xref>, <xref rid="jcmm13732-bib-0023" ref-type="ref">23</xref> It could up&#x02010;regulate a series of glycolytic genes during anaerobic glycolysis and then increase the glycolysis rate and ATP production. A previous study also suggested that glycolysis was necessary for maintaining HIF&#x02010;1&#x003b1; activity.<xref rid="jcmm13732-bib-0024" ref-type="ref">24</xref> In the present study, the glycolytic enzyme ALDOA was also found to increase HIF&#x02010;1&#x003b1; activity. Glycolysis and HIF&#x02010;1&#x003b1; formed a feed&#x02010;forward loop that stimulated tumour growth and metastases. When silencing the expression of ALDOA, the anaerobic glycolysis was inhibited, ATP levels were reduced, the feed&#x02010;forward loop was broken and tumour proliferation and metastases were inhibited. Conversely, the high expression of ALDOA could increase the HIF&#x02010;1&#x003b1; activity, and HIF&#x02010;1&#x003b1; could, in turn, promote glycolysis and EMT process. Hence, ALDOA may serve as a promising biomarker and target therapy for GC.</p><p>Several studies focused on the relationship between EMT and glycolysis. A previous study demonstrated that FBP1 was a negative regulator of EMT in GC.<xref rid="jcmm13732-bib-0018" ref-type="ref">18</xref> Loss of FBP1 by Snail&#x02010;mediated repression provided metabolic advantages in basal&#x02010;like breast cancer.<xref rid="jcmm13732-bib-0025" ref-type="ref">25</xref> The ectopic expression of aldolase B was associated with poor prognosis and promotes tumour progression by EMT in colorectal adenocarcinoma.<xref rid="jcmm13732-bib-0017" ref-type="ref">17</xref> Some oncogene and tumour suppressors had a crosstalk between EMT and glycolysis in cancer progression and metastases, such as HIF&#x02010;1&#x003b1;,<xref rid="jcmm13732-bib-0023" ref-type="ref">23</xref> c&#x02010;myc,<xref rid="jcmm13732-bib-0026" ref-type="ref">26</xref> FOXM1,<xref rid="jcmm13732-bib-0027" ref-type="ref">27</xref> Gas1,<xref rid="jcmm13732-bib-0028" ref-type="ref">28</xref> and so on. The present study suggested a novel function of ALDOA other than a glycolytic enzyme.</p><p>Collectively, this study provided firm evidence that ALDOA was crucial in GC by inducing the EMT pathway and affecting HIF&#x02010;1&#x003b1; activity in tumour progression and metastasis. The expression level of ALDOA was an independent adverse prognostic factor for both OS and DFS, providing additional information for guiding therapeutic strategies.</p></sec><sec id="jcmm13732-sec-0023"><title>CONFLICTS OF INTEREST</title><p>None.</p></sec></body><back><ack id="jcmm13732-sec-0022"><title>ACKNOWLEDGEMENTS</title><p>None.</p></ack><ref-list content-type="cited-references" id="jcmm13732-bibl-0001"><title>REFERENCES</title><ref id="jcmm13732-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0001">
<string-name>
<surname>Siegel</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Jemal</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cancer statistics, 2017</article-title>. <source xml:lang="en">CA Cancer J Clin</source>. <year>2017</year>;<volume>67</volume>:<fpage>7</fpage>&#x02010;<lpage>30</lpage>.<pub-id pub-id-type="pmid">28055103</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0002">
<string-name>
<surname>Moon</surname>
<given-names>YW</given-names>
</string-name>, <string-name>
<surname>Jeung</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Rha</surname>
<given-names>SY</given-names>
</string-name>, et al. <article-title>Changing patterns of prognosticators during 15&#x02010;year follow&#x02010;up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15&#x02010;year follow&#x02010;up study at a single korean institute</article-title>. <source xml:lang="en">Ann Surg Oncol</source>. <year>2007</year>;<volume>14</volume>:<fpage>2730</fpage>&#x02010;<lpage>2737</lpage>.<pub-id pub-id-type="pmid">17632757</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0003">
<string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Snail enhances glycolysis in the epithelial&#x02010;mesenchymal transition process by targeting FBP1 in gastric cancer</article-title>. <source xml:lang="en">Cell Physiol Biochem</source>. <year>2017</year>;<volume>43</volume>:<fpage>31</fpage>&#x02010;<lpage>38</lpage>.<pub-id pub-id-type="pmid">28848200</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0004">
<string-name>
<surname>Galizia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lieto</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Auricchio</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Comparison of the current AJCC&#x02010;TNM numeric&#x02010;based with a new anatomical location&#x02010;based lymph node staging system for gastric cancer: a western experience</article-title>. <source xml:lang="en">PLoS ONE</source>. <year>2017</year>;<volume>12</volume>:<fpage>e0173619</fpage>.<pub-id pub-id-type="pmid">28380037</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0005">
<string-name>
<surname>Gu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>The prognostic efficacy and improvements of the 7th edition Union for International Cancer Control tumor&#x02010;node&#x02010;metastasis classifications for Chinese patients with gastric cancer: results based on a retrospective three&#x02010;decade population study</article-title>. <source xml:lang="en">Tumour Biol</source>. <year>2017</year>;<volume>39</volume>:<fpage>1010428317694548</fpage>.<pub-id pub-id-type="pmid">28351302</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0006">
<string-name>
<surname>Wang</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>ZN</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>HM</given-names>
</string-name>. <article-title>Improvement of T stage precision by integration of surgical and pathological staging in radically resected stage pT3&#x02010;pT4b gastric cancer</article-title>. <source xml:lang="en">Oncotarget</source>. <year>2017</year>;<volume>8</volume>:<fpage>46506</fpage>&#x02010;<lpage>46513</lpage>.<pub-id pub-id-type="pmid">28148895</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0007">
<string-name>
<surname>Peng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer</article-title>. <source xml:lang="en">Mol BioSyst</source>. <year>2012</year>;<volume>8</volume>:<fpage>3077</fpage>&#x02010;<lpage>3088</lpage>.<pub-id pub-id-type="pmid">22996014</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0008">
<string-name>
<surname>Kawai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Munakata</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Fructose&#x02010;bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis</article-title>. <source xml:lang="en">Int J Oncol</source>. <year>2017</year>;<volume>50</volume>:<fpage>525</fpage>&#x02010;<lpage>534</lpage>.<pub-id pub-id-type="pmid">28000858</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0009">
<string-name>
<surname>Nagaraju</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Bramhachari</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Raghu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>El&#x02010;Rayes</surname>
<given-names>BF</given-names>
</string-name>. <article-title>Hypoxia inducible factor&#x02010;1alpha: its role in colorectal carcinogenesis and metastasis</article-title>. <source xml:lang="en">Cancer Lett</source>. <year>2015</year>;<volume>366</volume>:<fpage>11</fpage>&#x02010;<lpage>18</lpage>.<pub-id pub-id-type="pmid">26116902</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0010">
<string-name>
<surname>Schofield</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Ratcliffe</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Oxygen sensing by HIF hydroxylases</article-title>. <source xml:lang="en">Nat Rev Mol Cell Biol</source>. <year>2004</year>;<volume>5</volume>:<fpage>343</fpage>&#x02010;<lpage>354</lpage>.<pub-id pub-id-type="pmid">15122348</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0011">
<string-name>
<surname>Denko</surname>
<given-names>NC</given-names>
</string-name>. <article-title>Hypoxia, HIF1 and glucose metabolism in the solid tumour</article-title>. <source xml:lang="en">Nat Rev Cancer</source>. <year>2008</year>;<volume>8</volume>:<fpage>705</fpage>&#x02010;<lpage>713</lpage>.<pub-id pub-id-type="pmid">19143055</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0012">
<string-name>
<surname>DeBerardinis</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Lum</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Hatzivassiliou</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>CB</given-names>
</string-name>. <article-title>The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</article-title>. <source xml:lang="en">Cell Metab</source>. <year>2008</year>;<volume>7</volume>:<fpage>11</fpage>&#x02010;<lpage>20</lpage>.<pub-id pub-id-type="pmid">18177721</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0013">
<string-name>
<surname>Warburg</surname>
<given-names>O</given-names>
</string-name>. <article-title>On the origin of cancer cells</article-title>. <source xml:lang="en">Science</source>. <year>1956</year>;<volume>123</volume>:<fpage>309</fpage>&#x02010;<lpage>314</lpage>.<pub-id pub-id-type="pmid">13298683</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0014">
<string-name>
<surname>Garber</surname>
<given-names>K</given-names>
</string-name>. <article-title>Energy deregulation: licensing tumors to grow</article-title>. <source xml:lang="en">Science</source>. <year>2006</year>;<volume>312</volume>:<fpage>1158</fpage>&#x02010;<lpage>1159</lpage>.<pub-id pub-id-type="pmid">16728625</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0015">
<string-name>
<surname>Sanzey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Abdul Rahim</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Oudin</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma</article-title>. <source xml:lang="en">PLoS ONE</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0123544</fpage>.<pub-id pub-id-type="pmid">25932951</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0016">
<string-name>
<surname>Kim</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Dang</surname>
<given-names>CV</given-names>
</string-name>. <article-title>Multifaceted roles of glycolytic enzymes</article-title>. <source xml:lang="en">Trends Biochem Sci</source>. <year>2005</year>;<volume>30</volume>:<fpage>142</fpage>&#x02010;<lpage>150</lpage>.<pub-id pub-id-type="pmid">15752986</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0017">
<string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Aldolase B overexpression is associated with poor prognosis and promotes tumor progression by epithelial&#x02010;mesenchymal transition in colorectal adenocarcinoma</article-title>. <source xml:lang="en">Cell Physiol Biochem</source>. <year>2017</year>;<volume>42</volume>:<fpage>397</fpage>&#x02010;<lpage>406</lpage>.<pub-id pub-id-type="pmid">28558381</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0018">
<string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>QG</given-names>
</string-name>, et al. <article-title>Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial&#x02010;mesenchymal transition</article-title>. <source xml:lang="en">PLoS ONE</source>. <year>2016</year>;<volume>11</volume>:<fpage>e0167857</fpage>.<pub-id pub-id-type="pmid">27978536</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0019">
<string-name>
<surname>Ji</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>ALDOA functions as an oncogene in the highly metastatic pancreatic cancer</article-title>. <source xml:lang="en">Cancer Lett</source>. <year>2016</year>;<volume>374</volume>:<fpage>127</fpage>&#x02010;<lpage>135</lpage>.<pub-id pub-id-type="pmid">26854714</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0020">
<string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Zuo</surname>
<given-names>XY</given-names>
</string-name>, et al. <article-title>Elevated transcriptional levels of aldolase A (ALDOA) associates with cell cycle&#x02010;related genes in patients with NSCLC and several solid tumors</article-title>. <source xml:lang="en">BioData Min</source>. <year>2017</year>;<volume>10</volume>:<fpage>6</fpage>.<pub-id pub-id-type="pmid">28191039</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0021">
<string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>HIF&#x02010;1alpha promotes epithelial&#x02010;mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer</article-title>. <source xml:lang="en">PLoS ONE</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0129603</fpage>.<pub-id pub-id-type="pmid">26057751</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0022">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Hypoxia induces epithelial&#x02010;mesenchymal transition via activation of SNAI1 by hypoxia&#x02010;inducible factor &#x02010;1alpha in hepatocellular carcinoma</article-title>. <source xml:lang="en">BMC Cancer</source>. <year>2013</year>;<volume>13</volume>:<fpage>108</fpage>.<pub-id pub-id-type="pmid">23496980</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0023">
<string-name>
<surname>Robey</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Lien</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Welsh</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Baggett</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Gillies</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Hypoxia&#x02010;inducible factor&#x02010;1alpha and the glycolytic phenotype in tumors</article-title>. <source xml:lang="en">Neoplasia</source>. <year>2005</year>;<volume>7</volume>:<fpage>324</fpage>&#x02010;<lpage>330</lpage>.<pub-id pub-id-type="pmid">15967109</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0024">
<string-name>
<surname>Grandjean</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>de Jong</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>BP</given-names>
</string-name>, et al. <article-title>Definition of a novel feed&#x02010;forward mechanism for Glycolysis&#x02010;HIF1alpha signaling in hypoxic tumors highlights aldolase A as a therapeutic target</article-title>. <source xml:lang="en">Can Res</source>. <year>2016</year>;<volume>76</volume>:<fpage>4259</fpage>&#x02010;<lpage>4269</lpage>.</mixed-citation></ref><ref id="jcmm13732-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0025">
<string-name>
<surname>Dong</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Loss of FBP1 by Snail&#x02010;mediated repression provides metabolic advantages in basal&#x02010;like breast cancer</article-title>. <source xml:lang="en">Cancer Cell</source>. <year>2013</year>;<volume>23</volume>:<fpage>316</fpage>&#x02010;<lpage>331</lpage>.<pub-id pub-id-type="pmid">23453623</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0026">
<string-name>
<surname>Ji</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Qin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>FBW7 (F&#x02010;box and WD Repeat Domain&#x02010;Containing 7) negatively regulates glucose metabolism by targeting the c&#x02010;Myc/TXNIP (Thioredoxin&#x02010;Binding Protein) axis in pancreatic cancer</article-title>. <source xml:lang="en">Clin Cancer Res</source>. <year>2016</year>;<volume>22</volume>:<fpage>3950</fpage>&#x02010;<lpage>3960</lpage>.<pub-id pub-id-type="pmid">26983463</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0027">
<string-name>
<surname>Cui</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression</article-title>. <source xml:lang="en">Clin Cancer Res</source>. <year>2014</year>;<volume>20</volume>:<fpage>2595</fpage>&#x02010;<lpage>2606</lpage>.<pub-id pub-id-type="pmid">24634381</pub-id></mixed-citation></ref><ref id="jcmm13732-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jcmm13732-cit-0028">
<string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Qin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Gas1 inhibits metastatic and metabolic phenotypes in colorectal carcinoma</article-title>. <source xml:lang="en">Mol Cancer Res</source>. <year>2016</year>;<volume>14</volume>:<fpage>830</fpage>&#x02010;<lpage>840</lpage>.<pub-id pub-id-type="pmid">27401611</pub-id></mixed-citation></ref></ref-list></back></article>